Remove tag blockchain
article thumbnail

Blockchain for Supply Chain – Insights from Berlin

Tom Spencer

I recently sat down with blockchain aficionado Ricardo Garcia to gain some insights into the Berlin blockchain space. We dove into an hour-long Q&A session with three main objectives: To learn how Ricardo found himself in the blockchain world after working at a strategy consulting firm. I have a little nerdy side in me.

article thumbnail

What Blockchain Can’t Do

Harvard Business

Blockchain technology has the potential to do amazing things. However, when assessing blockchain business models, it is useful to understand what blockchain can’t do. But there is a big problem with using blockchain to solve such a problem. And this is where blockchain falls down. Jorg Greuel/Getty Images.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

8 Ways Brands Can Fight Counterfeits in China

Harvard Business

QR and RFID schemes can use blockchain technology to prevent fraud and counterfeiting. In order to improve product safety, China’s pharmaceutical, alcohol, and food industries already use QR codes and RFID tags to track products as they move from factory to consumer. Invest in anti-counterfeit technology.

article thumbnail

How Blockchain Could Help Emerging Markets Leap Ahead

Harvard Business

Much has been made of the potential for blockchain technologies to open up new vistas for business and society. We argue that, like previous revolutionary ideas, blockchain has the potential to help developing nations leapfrog more-developed economies. How Blockchain Works Here are five basic principles underlying the technology.

article thumbnail

3 Business Models That Could Bring Million-Dollar Cures to Everyone

Harvard Business

With a $1 million price tag, limited data on efficacy and just 700 potential patients in Europe, health systems were unwilling to pay for treatment. Consider what happened to Amsterdam-based UniQure. In 2016, the company had to pull its gene therapy for potentially fatal fat-processing deficiencies from the E.U.